Dr. Maryam Banikazemi of Columbia University is hosting a meeting for Pompe patients on July 16, 2010 in New York,

On May 24, 2010 the FDA approved Genzyme’s Lumizyme for the treatment of patients with Pompe disease who are over

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA has granted U.S. marketing approval for LumizymeTM (alglucosidase

To read a factual account of the true history of Pompe Disease, please visit Pompe Disease—The Real Story.

The AMDA issued a press release regarding the film, Extraordinary Measures. The press release can be found here. In addition,

This information was complied from the information provided on clinicaltrials.gov. To read, please download file by clicking here.

Genzyme would like to provide an update to the US Pompe community about the status of the Alglucosidase AlfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme. Temporary

Guidelines from Erasmus Medical Centre, Rotterdam, the Netherlands As a guideline we recommend that all patients with Pompe disease are

Genzyme Manufacturing Update Genzyme invites all patients to participate in a forum to discuss recent FDA reports and media attention